This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.12.037v1 49/14/1566    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Wang, X.-X. Articles by Chen, J.-Z. Search for Related Content PubMed Articles by Wang, X.-X. Articles by Chen, J.-Z. Related Collections Related Article

CLINICAL RESEARCH: PULMONARY VASCULAR DISEASE

Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension

A Pilot Randomized Controlled Trial

Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Manuscript received August 14, 2006; revised manuscript received December 6, 2006, accepted December 8, 2006.

^_* Reprint requests and correspondence: Dr. Jun-Zhu Chen, No. 79 Qingchun Road, Hangzhou, Zhejiang Province, People’s Republic of China, 310003. (Email: chenjz01{at}163.com).

Objectives: The goal of this study was to investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous endothelial progenitor cells (EPCs) in patients with idiopathic pulmonary arterial hypertension (IPAH).

Background: Experimental data suggest that transplantation of EPCs attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. In addition, clinical studies suggest that autologous progenitor cell transplantation is feasible and safe in patients with ischemic diseases.

Methods: We conducted a prospective, randomized trial comparing the effects of EPC transplantation plus conventional therapy with those of conventional therapy alone in patients with IPAH. The primary end point was change in the 6-min walk distance using a standardized protocol. The secondary end points were changes in hemodynamic variables as assessed by right heart catheterization.

Results: After 12 weeks of follow-up, the mean distance walked in 6 min increased by 48.2 m in the cell infusion group (from 263 ± 42 m to 312 ± 34 m), and an increase of 5.7 m occurred in the conventional therapy group (from 264 ± 42 m to 270 ± 44 m). The mean difference between the 2 groups was 42.5 m (95% confidence interval 28.7 to 56.3 m, p < 0.001). The patients in the cell infusion group also had significant improvement in mean pulmonary artery pressure, pulmonary vascular resistance, and cardiac output. There were no severe adverse events with cell infusion.

Conclusions: This preliminary study showed that intravenous infusion of autologous EPCs seemed to be feasible and safe, and might have beneficial effects on exercise capacity and pulmonary hemodynamics in patients with IPAH. (Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension; http://www.clinicaltrials.gov/ct/show/NCT00257413?order=1; NCT00257413 [ClinicalTrials.gov] ).

Abbreviations and Acronyms   EPC = endothelial progenitor cell   IPAH = idiopathic pulmonary arterial hypertension   MNC = mononuclear cell   PPH = primary pulmonary hypertension   VEGF = vascular endothelial growth factor

Related Article

Is it Possible to Reverse the Endothelial Dysfunction in Pulmonary Arterial Hypertension?

Robyn Barst
J. Am. Coll. Cardiol. 2007 49: 1572-1574. [Full Text] [PDF]

This article has been cited by other articles:

				E. D. Michelakis, M. R. Wilkins, and M. Rabinovitch Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension Circulation, September 30, 2008; 118(14): 1486 - 1495. [Full Text] [PDF]

				D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF]

				G.-P. Diller, S. van Eijl, D. O. Okonko, L. S. Howard, O. Ali, T. Thum, S. J. Wort, E. Bedard, J. S. R. Gibbs, J. Bauersachs, et al. Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension Circulation, June 10, 2008; 117(23): 3020 - 3030. [Abstract] [Full Text] [PDF]

				K. M. Chin and L. J. Rubin Pulmonary arterial hypertension. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]

				G. P. Fadini, M. Schiavon, F. Rea, A. Avogaro, and C. Agostini Depletion of Endothelial Progenitor Cells May Link Pulmonary Fibrosis and Pulmonary Hypertension Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 724 - 725. [Full Text] [PDF]

				N. K. Kapur Invited commentary Ann. Thorac. Surg., August 1, 2007; 84(2): 552 - 552. [Full Text] [PDF]

				R. Barst Is it Possible to Reverse the Endothelial Dysfunction in Pulmonary Arterial Hypertension? J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1572 - 1574. [Full Text] [PDF]